PubRank

Cancer immunology research (Cancer Immunol Res)

Journal PubWeight™ 377.02‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. 2013 2.76
2 PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. 2013 2.30
3 An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. 2013 2.30
4 In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. 2014 2.26
5 Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. 2014 2.25
6 PD-L1 expression in triple-negative breast cancer. 2014 2.06
7 Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. 2014 2.00
8 Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. 2014 1.79
9 The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. 2014 1.69
10 Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. 2014 1.62
11 Bevacizumab plus ipilimumab in patients with metastatic melanoma. 2014 1.54
12 Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. 2013 1.47
13 T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. 2016 1.44
14 Combining radiation and immunotherapy: a new systemic therapy for solid tumors? 2014 1.43
15 MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. 2014 1.40
16 PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. 2014 1.40
17 T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. 2013 1.39
18 HLA-binding properties of tumor neoepitopes in humans. 2014 1.37
19 Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. 2015 1.35
20 Getting personal with neoantigen-based therapeutic cancer vaccines. 2013 1.32
21 Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. 2015 1.31
22 Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. 2013 1.29
23 Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. 2013 1.28
24 Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. 2014 1.27
25 Individual Motile CD4(+) T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells. 2015 1.25
26 Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFNγ-dependent cell-cycle arrest. 2014 1.25
27 NKG2D Receptor and Its Ligands in Host Defense. 2015 1.25
28 STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. 2014 1.24
29 Oncolytic viruses and their application to cancer immunotherapy. 2014 1.23
30 Programmed cell death ligand 1 expression in osteosarcoma. 2014 1.23
31 Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. 2014 1.21
32 Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. 2015 1.20
33 Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. 2013 1.20
34 NF-κB, an active player in human cancers. 2014 1.19
35 Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. 2015 1.18
36 CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells. 2015 1.18
37 Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. 2014 1.17
38 Tim-3: an emerging target in the cancer immunotherapy landscape. 2014 1.17
39 CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. 2014 1.17
40 Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. 2015 1.17
41 Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. 2013 1.16
42 Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. 2013 1.16
43 Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. 2013 1.15
44 T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. 2013 1.14
45 PD-1 Restrains Radiotherapy-Induced Abscopal Effect. 2015 1.14
46 Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation. 2013 1.13
47 Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. 2013 1.12
48 Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. 2013 1.11
49 PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. 2015 1.08
50 Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. 2013 1.07
Next 50